Where does Teijin Pharma Limited rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Teijin Pharma Limited ranks #4,740 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Teijin Pharma Limited hold?

Teijin Pharma Limited holds 74 US utility patents granted between 2015 and 2025, spanning 35 technology areas.

What is Teijin Pharma Limited's Innovation Score?

Teijin Pharma Limited has an Innovation Score of 49.0 out of 100 (top 16% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Teijin Pharma Limited's patent grant rate increasing or decreasing?

Teijin Pharma Limited's recent grant velocity is -36% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Teijin Pharma Limited's patents?

Teijin Pharma Limited's patents average 13.3 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Teijin Pharma Limited patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Teijin Pharma Limited

Q: What technology areas does Teijin Pharma Limited focus on?

Teijin Pharma Limited's top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 31 patents. Grants appear in 35 CPC subclasses total.

USPTO PatentsView assignee record - 74 granted patents across 35 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Teijin ranks #4,740 of 49,997 tracked US assignees by granted-patent volume, with 74 patents across 35 technology areas.

#4,740
of 49,997 US assignees by volume: Top 16%
by Innovation Score (49.0/100): 13.3
avg claims per patent: -36%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R4740 · Foreign Corporation #4,740 · 74 grants

GRANTS-SMALL · TOP-DECILE · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · VEL-DOWN · BOOK-FULL

GRANTS-SMALL 74 grants
TOP-DECILE #4,740/49,997
PHOTO-FINISH Sotera Wireless
CPC-FOCUS A61P · 35 areas
INNOV-PAR 49.0/100
CLAIMS-RICH 13.3 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DOWN -36% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Sotera Wireless, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Fiberlean · near

49
Cambridge Display… · near

49
Sigma-Aldrich · near

49
Teijin Pharma · this assignee

49
Via Science · near

49
3D Lighting… · lowest

7

What this shows Teijin's Innovation Score is 49.0/100 (top 16% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Teijin's grants concentrate

Teijin Pharma Limited is a focused PatentsView assignee: 35 CPC subclasses with 41.9% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2019 (11 grants) versus a trough of 4 in 2024. By volume, Teijin sits between Sotera Wireless, Inc. and WM Intellectual Property Holdings, L.L.C..

Teijin's three-year grant acceleration

From 2019–2021 to 2022–2024, Teijin Pharma Limited moved from 22 to 17 grants (0.77x the prior three-year total, a multiple, not a CAGR). See the growth leaderboard.

Sotera Wireless

74
Taiyo Nippon Sanso

74
TDK—Micronas

74
Teva Pharmaceutic…

74
Tokyo Seimitsu

74
Universite Paris-…

74
Victor Equipment

74
WM Intellectual P…

74
Teijin Pharma ◀

74

What this shows Teijin holds 74 patents at rank #4,741, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Teijin

By rank, the assignees closest to #4,741 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Teijin's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Teijin, neither rank-band nor same-CPC leaders (those blocks stay above).

Similar innovation score

Nearest assignees by Innovation Score (49 here).

Sigma-Aldrich Co. LLC 49 Cambridge Display Technology Limited 49 Via Science, Inc. 49 Fiberlean Technologies Limited 49

Similar claim depth

Nearest assignees by average claims per patent (13.3 here).

Element Six Limited 13.3 avg China Unionpay Co., Ltd. 13.3 avg Erbe Elektromedizin GmbH 13.3 avg Toshiba Electronic Devices & Storage Corporation 13.3 avg

Teijin's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

49 Top 16% higher than 84% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Teijin Pharma Limited patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	10	13.5%
2016	6	8.1%
2017	8	10.8%
2018	9	12.2%
2019	11	14.9%
2020	6	8.1%
2021	5	6.8%
2022	7	9.5%
2023	6	8.1%
2024	4	5.4%
2025partial year	2	2.7%

Which technologies does Teijin Pharma Limited patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 31

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 20

A61B - DIAGNOSIS; SURGERY; Identification 18

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 17

C07D - Heterocyclic Compounds 17

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy 13

G16H - Healthcare Informatics, i.e. Information AND Communication Technology [ICT] Specially Adapted FOR THE Handling OR Processing OF Medical OR Healthcare Data 8

C07K - Peptides 6

A63B - Apparatus FOR Physical Training, Gymnastics, Swimming, Climbing, OR FENCING; Ball GAMES; Training Equipment 5

A61H - Physical Therapy Apparatus, e.g. Devices FOR Locating OR Stimulating Reflex Points IN THE BODY; Artificial RESPIRATION; MASSAGE; Bathing Devices FOR Special Therapeutic OR Hygienic Purposes OR Specific Parts OF THE Body 5

C01B - Non-metallic ELEMENTS; Compounds THEREOF; ; Metalloids OR Compounds Thereof NOT Covered BY Subclass C01c 5

B01D - Separation 5

C07C - Acyclic OR Carbocyclic Compounds 5

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 4

Y02P - Climate Change Mitigation Technologies IN THE Production OR Processing OF Goods 4

Top 15 of 35 technology areas

Where it ranks

Overall rank by patents

#4,740

of 49,997 tracked assignees

Innovation Score

49.0 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Teijin Pharma Limited's patent record in context - here's where to go next.

Teijin Pharma Limited's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 41.9% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #4,740 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Teijin Pharma Limited against Sotera Wireless, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 49.0/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.